% | $
Quotes you view appear here for quick access.

Genomic Health Inc. Message Board

  • terry_amln terry_amln Aug 28, 2013 12:21 PM Flag

    OncoMed successful IPO in July and GHDX

    Genomic Health and OncoMed Pharmaceuticals announced they have signed an agreement to identify new biomarkers useful for future companion diagnostics to go along with the latter's cancer drugs now in development.OncoMed will give Genomic Health samples of breast, prostate, colon and lung tumors, some of which will be taken from its proprietary bank of xenograft models. In turn, Genomic Health will use its molecular diagnostics to ferret out any biomarkers that would work best for personalized medicine-focused cancer treatments. Those biomarkers would enable clinicians to pick patient subsets likely to respond best to drugs targeting certain molecular pathways crucial for cancer stem cells.Companion diagnostics are the way to go in the future, Good Luck

    SortNewest  |  Oldest  |  Most Replied Expand all replies
29.55-1.04(-3.40%)Apr 27 4:00 PMEDT